Asthma Market

18
Asthma Market: US Currently $15 billion Projected to reach $17 billion by 2010 Major Players GSK - Advair(Fluticasone/salmeterol) AstraZeneca – Symbicort(Budesonide/ Formoterol) Merck - Singulair(Montelukast) Cipla -Indian Market (56.9% share of the asthma market) Source: www.wikinvest.com/concept/Asthma_drug_market Bussiness Insight: The Indian Pharmaceutical Market Outlook to 2014

Transcript of Asthma Market

Page 1: Asthma Market

Asthma Market: US

Currently $15 billion Projected to reach $17 billion by 2010 Major Players

GSK - Advair(Fluticasone/salmeterol) AstraZeneca – Symbicort(Budesonide/ Formoterol) Merck - Singulair(Montelukast) Cipla -Indian Market (56.9% share of the asthma

market)

Source: www.wikinvest.com/concept/Asthma_drug_marketBussiness Insight: The Indian Pharmaceutical Market Outlook to 2014

Page 2: Asthma Market

Asthma Drugs: US Market

Source: “Asthma & COPD-Clearing the air” 18 June 2007

Page 3: Asthma Market

Asthma Drugs: US Market

Source: GSK 2007 20-Fpg.11 , AZN 2007 20-F pg.1 MRK 2007 10-K pg.4

Page 4: Asthma Market

Asthma: India

2008 100,000 units of nebulizers sold at a total value of

Rs.10 crores 2009

Expected that 1,20,000 units will be sold in Indian market at a value of more than Rs.11 crores

CAGR(Compound Annual Growth Rate) Currently growing at 20% Future growth rate expected to be 25%

Source: www.medicalbuyer.co.in/2007/competitive-yet-growing-market-of nebulizers-1727

Page 5: Asthma Market

Asthma: India

Source: www.medicalbuyer.co.in/2007/competitive-yet-growing-market-of-nebulizers-1727-41.html

Page 6: Asthma Market

Prevalence in US & EU

Although UK stands out as the country which carries a greater disease burden related To asthma than any other country analyzed, prevalence of asthma is estimated to be Increasing in the other major markets, as there is less difference between pediatric prevalence rates for asthma between the UK & some of the other major markets

Page 7: Asthma Market

Asthma/COPD first/second-line brands by company & type-2004

Page 8: Asthma Market

World Top Ten Respiratory Drugs 2008

Generic Name Brands Companies Indications Sales

2006 2007 2008

Advair GSK Asthma 6.13 7 7.5

Montelukast Singulair Merck Asthma 3.56 4.3 4.3

Tiotropium Spriva COPD 1.74 2.5 1.9

Symbicort AstraZeneca Asthma 1.2 1.5 1.5

Budesonide Pulmicort AstraZeneca Asthma 1.3 1.4 1.2

Mometasone Nasonex Allergic rhinitis 0.94 1.1 1.3

Fluticasone Flovent, Flixotide GSK Asthma 1.22 1.25 1.2

Fexofenadine Allegra, Telfas Sanofi-Aventis Allergic rhinitis 0.86 0.99 1.1

Cetrizine Zyrtec Allergic rhinitis 2.4 2.2 1.9

Fluticasone Salmetrol

Boehringer Ingelheim, Pfizer

Budesonide + Formoterol

Schering-Plough Sanofi Aventis

Pfizer,UCB, Daiichi Sankyo

Source: Global Respiratory Market Review & World Top Ten Respiratory Drugs 2008

Page 9: Asthma Market

Top 10 Products

Page 10: Asthma Market

Top 10 Products

GSK AstraZeneca

GSK

Page 11: Asthma Market

Top 10 Products

Sanofi Aventis

Pfizer,UCB, Daiichi

Page 12: Asthma Market

Allergy Pipeline: July 1999-2009

Indication Phase Revision date

Omalizumab Genentech Allergic asthma June 2009

Allergy/ Asthma Preclinical Jan 2007

Allergic asthma Preclinical Jan 2007

Ragweed Allergy Vaccine Allergic rhinitis Pre-registration Mar 2009

Seasonal allergic rhinitis Phase III

Circassia (UK) Phase II May 2009

Seasonal allergic rhinitis Phase II Nov 2008

Curalogic (DK) Allergy Discontinued III Dec 2007

Molecule Company

Launched (AU, BR, CA, EU

unioin, NZ, CH USA)

Anti-IgE allergy vaccine

United Biomedical (USA)

Anti -C5 Mab therapy Alexion Pharmaceuticals

(USA)

Pollinex /Quattro (Allergy Vaccine)

Allergy Therapeutics Licensee:

Allerpharma Ragweed allergy

vaccine sublingual Greer Laboratories

(USA) June 2008

Ragweed Allergy Vaccine

Seasonal Allergic Rhinitis

Ragweed allergy vaccine tablet

ALK-Abello(DK) /Schering Plough

Microencapsulated ragweed pollen

extract

Page 13: Asthma Market

Allergy Pipeline: July 1999-2009Indication Phase Revision date

House dust mite allergy vaccine tablet Phase II April 2009

Phase II Mar 2008

Greer Laboratories Allergic rhinitis Phase I Mar 2009

Allergy vaccine subcutaneous Allergy Therapeutics Allergy Preclinical Feb 2007Anti allergy vaccine tablet ALK-Abello (DK) Preclinical Jan 2007

Phylogica (AU) Allergy Preclinical Sep 2005

Dust mite allergy vaccine Allergic asthma Preclinical Aug 2004

Allergy vaccine University of Edinburgh (UK) Allergy Mar 2007

Novozymes Allergy Nov 2005

Molecule Company

Oralair Mites (House dust mite allergy vaccine tablet )

Stallergens SA (FR)/Paladin Labs; Solvay

Pharmaceuticals

Perennial allergic rhinitis

ALK Mite tablet (House dust mite allergy

vaccine tablet )

ALK-Abello(DK) /Schering Plough

Allergic asthma/ Allergic rhinitis

House dust mite allergy vaccine

Allergic asthma/rhinitis

Phylogica (House dust mite allergy vaccine )

National University of Singapore

Discontinued Preclinical

House dust mite allergy vaccine Discontinued Preclinical

Page 14: Asthma Market

Allergy Pipeline: July 1999-2009Indication Phase Revision date

Others ALK-Abello (DK) Seasonal allergic rhinitis Mar 2009

Seasonal allergic rhinitis Pre-registration Jan 2009

Allergopharma (DE) Allergy Phase III April 2009

Allergopharma (DE) Allergy Phase III Mar 2003

Asthma Phase II May 2006

MEM 1414 Allergic asthma Phase II 2009

Allergic asthma Phase II 2009

Allergy Phase I Feb 2007

Perennial allergic rhinitis Phase I Dec 2005

Molecule Company

Grazax (Grass pollen allergy vaccine tablet)

Launched(DK, DE, NO, SE,

UK) Oralgen grasspollen (Grass pollen allergy

vaccine)

Fornix Biosciences (NL)

Wasp venom allergy vaccine

Bee venom allergy vaccine

MAP3K9 kinase inhibitors

DeCODE genetics (Iceland) Memory

Pharmaceuticals Mometasone/formoterol

Schering Plough/ Novartis

Sublingual allergy vaccine

Allergy Therapeutics (UK)

Cat allergy vaccine sublingual

Greer Laboratories (USA)

Page 15: Asthma Market

Allergy Pipeline: July 1999-2009

Indication Phase Revision date

Others HAE 1 Genentech Allergic asthma Phase I 2009

QAX 935 Idera Pharmaceuticals Allergic asthma Phase I 2009R 343 Rigel Pharmaceuticals Allergic asthma Phase I 2009

Allergy vaccine VLP Biotech (USA) Allergy Preclinical Dec 2004Allergy Preclinical Sep 2008

AFM 19 Allergy/ Asthma Preclinical July 2005

Asthma therapy Asthma Preclinical Oct 2007

NX 401 Novavax (USA) Allergy Preclinical July 2005Allery /Asthma Preclinical July 2003

Molecule Company

(E)-2-(3-(3-(3-Bromophenylamino)-2-cyano-3-oxoprop-1-

enyl)-1H-indol-1-yl)acetic acid

Actelion Pharmaceuticals (CH)

Affirmed Therapeutics (DE)

Schering Plough ; Oscient Pharmaceuticals

Allergy/Asthma therapy

Rigshospitalet; Santaris (DK)

Page 16: Asthma Market

Allergy Pipeline: July 1999-2009Indication Phase Revision date

Others 1217B Asthma Preclinical Aug 2007

PYM 60001 Phytopharm (England) Asthma Preclinical July 2007

PRS 060 Pieris (DE) Asthma Preclinical July 2007SRP312 SR Pharma (England) Asthma Preclinical May 2007

Tryptase inhibitirs Selecore (DE) Asthma Preclinical Sep 2005Targepeutics Allergic asthma Preclinical Sep 2005

Asthma therapy Asthma Preclinical May 2005

ME-108 Pharmexa (DK) Allergy Mar 2007

Unknown Food allergy Apr 2002

Allergy vaccine Food allergy Discontinued II July 1999

Allergy Mar 2008

Molecule Company

Medigreen Biotechnology Corp(CN)

TARG-ALLERG 1-200

Celestar Lexico Sciences (JP)

Discontinued Preclinical

Food Allergy DNA Vaccine

No development reported

University of Brimingham / GSK Acambis

Asthma/Allergy therapy Boehringer Ingelheim; J&J

Discontinued Preclinical

Page 17: Asthma Market

Allergy Pipeline: July 1999-2009Indication Phase

Other Allergy therapy Allergy Discontinued Preclinical Dec 2007

Allergy therapy Allergy Discontinued Preclinical Aug 2007

Maxy 320 Maxygen /ALK-Abello Allergic asthma Discontinued Preclinical Jan 2007

Allergy therapy & Diagnostics ImmavaRx (USA) Allergy No development reported Feb 2006

Asthma/Allergy therapy Amgen Allergy/asthma No development reported Aug 2001

E-CpG ODN CJ Corporation (SK) Allergic asthma Discontinued Preclinical Aug 2007

Asthma therapy Asthma Discontinued Preclinical Dec 2006

Asthma therapy OSI Pharmaceuticals Asthma No development reported June 2006

PLIVA ; PLR 8 PLIVA (Croatia) Asthma Discontinued Preclinical May 2006

Stress Protein allergy therapy Allergy/Asthma Discontinued Preclinical Oct 2002

VMR 001 Vernalis Group (UK) Asthma Discontinued Preclinical May 2001

Molecule Company Revision date

Kyorin Pharmaceuticals (JP); Infinity

Pharmaceuticals (USA) Katolinska Institute (SE)

; Maxygen (USA)

Sirna Therapeutics (USA)

Nventa Biopharmaceuticals

(USA)

Page 18: Asthma Market

Allergy Pipeline: July 1999-2009

Indication Phase Revision date

Allergic Rhinitis Allergy Vaccine Allergy Therapeutics Allergic rhinitis Phase III 2009

CP 118 Collegium Pharmaceuticals Allergic rhinitis Phase II 2009

Curalogic Allergy Phase II 2009

Z-207 Zeria Allergic rhinitis Phase I Aug 2008AVP 13358 Avanair Pharmaceuticals Phase I 2009

GSK 1004723 Boehringer Ingelheim Allergic rhinitis Phase I 2009Emisphere Allergy Phase I 2009

ALR 8 Topigen Pharmaceuticals Allergic rhinitis Preclinical Dec 2005

Allergic conjunctivitis Alcaftadine Vistakon Pharmaceuticals Allergic conjunctivitis Phase III 2009

Betotastine Ube Industries Allergic conjunctivitis Pre-registration 2009

K 123 Kowa Allergic conjunctivitis Phase II 2009

Fovea Pharmaceuticals Allergic conjunctivitis Phase II 2009

Molecule Company

Microencapsulated cat hair extract

Allergic rhinitis / asthma

Sodium cromoglicate oral

Prednisolone/ ciclosporin